General Medicine Adds GLP-1 Weight Management Care to Eli Lilly's LillyDirect
General Medicine integrates its GLP-1 weight management care into Eli Lilly's LillyDirect platform, offering transparent pricing and same-day access for patients across…
General Medicine integrates its GLP-1 weight management care into Eli Lilly's LillyDirect platform, offering transparent pricing and same-day access for patients across…
Eli Lilly has commenced construction on a $3.5 billion facility in Pennsylvania to expand production capacity for injectable obesity medicines, with the…
Eli Lilly's Foundayo met primary endpoints in the ATTAIN-OSA trial, showing significant reductions in sleep apnea severity and body weight, with an…
Eli Lilly shares see potential upside as Phase 3 trials for retatrutide show substantial efficacy in treating knee osteoarthritis and obesity, with…
Eli Lilly faces fresh legal scrutiny as Parker Waichman files multiple lawsuits alleging a link between the blockbuster drug Mounjaro and cases…
Eli Lilly and Company submitted an 8-K filing to the SEC, outlining its current financial condition and operational results as part of…
Eli Lilly reports a 39% revenue jump to $24.4 billion in Q3 2026, driven by high demand for Mounjaro and Zepbound, leading…
Eli Lilly confirms a planned leadership succession with Ilya Yuffa succeeding retiring executive Patrik Jonsson in 2027, maintaining current financial guidance as…
Eli Lilly maintains its shareholder return strategy by declaring a $1.73 per share dividend, payable to stockholders of record this December.
Eli Lilly's sofetabart mipitecan shows strong clinical efficacy in ovarian cancer trials, achieving a 100% disease control rate in combination therapy.
Eli Lilly eyes label expansion for Omvoh after pediatric ulcerative colitis trial data shows 80% induction response rate, strengthening the drug's clinical…
Eli Lilly prepares to present key clinical trial updates for its investigational oncology candidates, including sofetabart mipitecan and olomorasib, at the upcoming…